{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:21:55Z","timestamp":1786980115189,"version":"build-2736575974"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2024,5,9]],"date-time":"2024-05-09T00:00:00Z","timestamp":1715212800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,5,9]],"date-time":"2024-05-09T00:00:00Z","timestamp":1715212800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Klinikum der Universit\u00e4t M\u00fcnchen"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur Arch Otorhinolaryngol"],"published-print":{"date-parts":[[2024,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Allergic rhinits is a prevalent condition, affecting a substantial proportion of the population. This study investigates the impact of ongoing biologic therapy, specifically with Dupilumab, on allergy diagnostics in patients with allergic rhinits.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Various tests, including the Skin Prick Test, serum IgE levels and Allergy Screening Panels, were examined for their effectiveness in detecting sensitizations during biologic treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The results indicate a significant decline in total IgE levels following biologic therapy initiation, aligning with previous findings on Dupilumab's inhibitory effects on IL-4 and IL-13. However, the specific IgE to total IgE ratio for major allergens was not significantly reduced. Comparing diagnostic tools, the Skin Prick Test demonstrates an impressive retention rate of sensitizations (98%) during Dupilumab treatment, outperforming the Allergy Screening Panel, which shows a 75% detection rate. Notably, the panel displays limitations in capturing lower sensitization levels.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>In summary, this study underscores that, despite the influence of biologic therapy on certain markers, standard allergy tests remain viable while emphasizing the importance of considering specific IgE levels rather than relying solely on CAP classes. The Skin Prick Test in particular proves to be a reliable tool for identifying sensitizations during Dupilumab treatment. The results offer valuable guidance for the diagnostic management of Allergic rhinits in individuals subjected to Dupilumab treatment.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00405-024-08700-2","type":"journal-article","created":{"date-parts":[[2024,5,9]],"date-time":"2024-05-09T10:01:56Z","timestamp":1715248916000},"page":"4183-4190","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Diagnostics of allergic rhinitis under dupilumab therapy"],"prefix":"10.1007","volume":"281","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6962-9999","authenticated-orcid":false,"given":"Patrick","family":"Huber","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moritz","family":"Gr\u00f6ger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clemens","family":"Stihl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanna","family":"Frankenberger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mattis","family":"Bertlich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Haubner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donata","family":"Gellrich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,5,9]]},"reference":[{"issue":"2","key":"8700_CR1","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/j.iac.2015.12.002","volume":"36","author":"EO Meltzer","year":"2016","unstructured":"Meltzer EO (2016) Allergic Rhinitis: Burden of Illness, Quality of Life, Comorbidities, and Control. Immunol Allergy Clin North Am 36(2):235\u2013248","journal-title":"Immunol Allergy Clin North Am"},{"issue":"9809","key":"8700_CR2","doi-asserted-by":"publisher","first-page":"2112","DOI":"10.1016\/S0140-6736(11)60130-X","volume":"378","author":"AN Greiner","year":"2011","unstructured":"Greiner AN, Hellings PW, Rotiroti G, Scadding GK (2011) Allergic rhinitis. Lancet 378(9809):2112\u20132122","journal-title":"Lancet"},{"issue":"Suppl 85","key":"8700_CR3","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1111\/j.1398-9995.2007.01549.x","volume":"62","author":"GW Canonica","year":"2007","unstructured":"Canonica GW, Bousquet J, Mullol J, Scadding GK, Virchow JC (2007) A survey of the burden of allergic rhinitis in Europe. Allergy 62(Suppl 85):17\u201325","journal-title":"Allergy"},{"issue":"6","key":"8700_CR4","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1016\/j.coi.2007.08.004","volume":"19","author":"A Kato","year":"2007","unstructured":"Kato A, Schleimer RP (2007) Beyond inflammation: airway epithelial cells are at the interface of innate and adaptive immunity. Curr Opin Immunol 19(6):711\u2013720","journal-title":"Curr Opin Immunol"},{"issue":"2","key":"8700_CR5","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1016\/j.iac.2015.12.004","volume":"36","author":"DI Bernstein","year":"2016","unstructured":"Bernstein DI, Schwartz G, Bernstein JA (2016) Allergic Rhinitis: Mechanisms and Treatment. Immunol Allergy Clin North Am 36(2):261\u2013278","journal-title":"Immunol Allergy Clin North Am"},{"issue":"1","key":"8700_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.18176\/jiaci.0769","volume":"32","author":"O Luengo","year":"2022","unstructured":"Luengo O, Labrador-Horrillo M (2022) Molecular Allergy Diagnosis in Clinical Practice: Frequently Asked Questions. J Investig Allergol Clin Immunol 32(1):1\u201312","journal-title":"J Investig Allergol Clin Immunol"},{"key":"8700_CR7","doi-asserted-by":"crossref","unstructured":"Fokkens WJ, Lund VJ, Hopkins C, Hellings PW, Kern R, Reitsma S, et al. European Position Paper on Rhinosinusitis and Nasal Polyps 2020. Rhinology. 2020;58(Suppl S29):1\u2013464.","DOI":"10.4193\/Rhin20.601"},{"issue":"3","key":"8700_CR8","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1016\/j.jaip.2020.09.063","volume":"9","author":"TM Laidlaw","year":"2021","unstructured":"Laidlaw TM, Mullol J, Woessner KM, Amin N, Mannent LP (2021) Chronic Rhinosinusitis with Nasal Polyps and Asthma. J Allergy Clin Immunol Pract 9(3):1133\u20131141","journal-title":"J Allergy Clin Immunol Pract"},{"key":"8700_CR9","unstructured":"GmbH S-AD. Dupixent 300 mg Injektionsl\u00f6sung im Fertigpen\/-in einer Fertigspritze Rote Liste2023 [Available from: https:\/\/www.rote-liste.de\/suche\/praep\/26905\/Dupixent%20300%20mg%20Injektionsl%C3%B6sung%20in%20einer%20Fertigspritze%20%20Fertigspritzen%20mit%20automatischem%20Sicherheitssystem."},{"issue":"1","key":"8700_CR10","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1111\/cea.13491","volume":"50","author":"H Harb","year":"2020","unstructured":"Harb H, Chatila TA (2020) Mechanisms of Dupilumab. Clin Exp Allergy 50(1):5\u201314","journal-title":"Clin Exp Allergy"},{"issue":"1","key":"8700_CR11","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/s40413-016-0122-3","volume":"9","author":"ML Kowalski","year":"2016","unstructured":"Kowalski ML, Ansotegui I, Aberer W, Al-Ahmad M, Akdis M, Ballmer-Weber BK et al (2016) Risk and safety requirements for diagnostic and therapeutic procedures in allergology: World Allergy Organization Statement. World Allergy Organ J 9(1):33","journal-title":"World Allergy Organ J"},{"issue":"10","key":"8700_CR12","doi-asserted-by":"publisher","first-page":"2684","DOI":"10.1111\/all.15796","volume":"78","author":"RJL van der Lans","year":"2023","unstructured":"van der Lans RJL, Otten JJ, Adriaensen G, Hoven DR, Benoist LB, Fokkens WJ, Reitsma S (2023) Two-year results of tapered dupilumab for CRSwNP demonstrates enduring efficacy established in the first 6 months. Allergy 78(10):2684\u20132697","journal-title":"Allergy"},{"issue":"10","key":"8700_CR13","doi-asserted-by":"publisher","first-page":"2669","DOI":"10.1111\/all.15772","volume":"78","author":"E De Corso","year":"2023","unstructured":"De Corso E, Pasquini E, Trimarchi M, La Mantia I, Pagella F, Ottaviano G et al (2023) Dupilumab in the treatment of severe uncontrolled chronic rhinosinusitis with nasal polyps (CRSwNP): A multicentric observational Phase IV real-life study (DUPIREAL). Allergy 78(10):2669\u20132683","journal-title":"Allergy"},{"issue":"2","key":"8700_CR14","doi-asserted-by":"publisher","first-page":"413","DOI":"10.47162\/RJME.63.2.12","volume":"63","author":"A Iordache","year":"2022","unstructured":"Iordache A, Balica NC, Horhat ID, Morar R, Tischer AA, Milcu AI et al (2022) Allergic rhinitis associated with nasal polyps and rhinosinusitis - histopathological and immunohistochemical study. Rom J Morphol Embryol 63(2):413\u2013419","journal-title":"Rom J Morphol Embryol"},{"issue":"6","key":"8700_CR15","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1002\/cpdd.798","volume":"9","author":"Z Li","year":"2020","unstructured":"Li Z, Radin A, Li M, Hamilton JD, Kajiwara M, Davis JD et al (2020) Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Dupilumab in Healthy Adult Subjects. Clin Pharmacol Drug Dev 9(6):742\u2013755","journal-title":"Clin Pharmacol Drug Dev"},{"issue":"10209","key":"8700_CR16","doi-asserted-by":"publisher","first-page":"1638","DOI":"10.1016\/S0140-6736(19)31881-1","volume":"394","author":"C Bachert","year":"2019","unstructured":"Bachert C, Han JK, Desrosiers M, Hellings PW, Amin N, Lee SE et al (2019) Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials. Lancet 394(10209):1638\u20131650","journal-title":"Lancet"},{"issue":"3","key":"8700_CR17","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1111\/all.15591","volume":"78","author":"LS Spekhorst","year":"2023","unstructured":"Spekhorst LS, van der Rijst LP, de Graaf M, van Megen M, Zuithoff NPA, Knulst AC et al (2023) Dupilumab has a profound effect on specific-IgE levels of several food allergens in atopic dermatitis patients. Allergy 78(3):875\u2013878","journal-title":"Allergy"},{"issue":"4","key":"8700_CR18","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1002\/alr.23090","volume":"13","author":"SK Wise","year":"2023","unstructured":"Wise SK, Damask C, Roland LT, Ebert C, Levy JM, Lin S et al (2023) International consensus statement on allergy and rhinology: Allergic rhinitis - 2023. Int Forum Allergy Rhinol 13(4):293\u2013859","journal-title":"Int Forum Allergy Rhinol"}],"container-title":["European Archives of Oto-Rhino-Laryngology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00405-024-08700-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00405-024-08700-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00405-024-08700-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,23]],"date-time":"2024-07-23T04:09:22Z","timestamp":1721707762000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00405-024-08700-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,9]]},"references-count":18,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["8700"],"URL":"https:\/\/doi.org\/10.1007\/s00405-024-08700-2","relation":{},"ISSN":["0937-4477","1434-4726"],"issn-type":[{"value":"0937-4477","type":"print"},{"value":"1434-4726","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,9]]},"assertion":[{"value":"28 December 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 April 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 May 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"MG has received speaker honoration from Sanofi, GSK and Novartis. All other authors declare that there are no financial or non-financial interests that are directly or indirectly related to the submitted work.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}